Oren Gilad
Algemeen Directeur bij APREA THERAPEUTICS, INC.
Vermogen: 2 M $ op 30-04-2024
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Richard Peters | M | 61 | 4 jaar | |
| John Hamill | M | 60 | 1 jaar | |
| Michael Grissinger | M | 70 |
Atrin Pharmaceuticals LLC
 Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | 6 jaar |
| Bernd Seizinger | M | 67 | 9 jaar | |
| John Henneman | M | 62 | 5 jaar | |
| Rifat Pamukcu | M | 66 | 2 jaar | |
| Bernard Rudnick | M | - |
Atrin Pharmaceuticals LLC
Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | 9 jaar |
| Marc Duey | M | 68 | 2 jaar | |
| Gabriela Gruia | M | 67 | 1 jaar | |
| Zeev Weiss | M | 62 | 2 jaar | |
| Jeffrey Dayno | M | 66 |
Atrin Pharmaceuticals LLC
Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | 8 jaar |
| Jean Bizzari | M | 69 | 1 jaar | |
| Benjamin R. Cowen | M | 63 |
Atrin Pharmaceuticals LLC
Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | 12 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Christian Schade | M | 63 | 7 jaar | |
| Michael Kelly | M | 67 | 2 jaar | |
| Scott Coiante | M | 57 | 4 jaar | |
| Fouad Namouni | M | 55 | 2 jaar | |
| Gregory Korbel | M | 48 | 7 jaar | |
| Lars Abrahmsén | M | 66 | 8 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigde Staten | 19 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Oren Gilad
- Persoonlijk netwerk